These findings imply that CTLA-4-Ig blocking and/or reduction of CD80 and CD86 on the surface of the memory B cells negatively correlates with disease activity and may predict a good clinical response in RA patients. This evidence concerns the gene CTLA4 and rheumatoid arthritis.